Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630361 | 0.99 | MME (0.54) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL30122989 | 0.99 | MME (0.54) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL30123104 | 0.96 | ENPEP (0.56) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL29619568 | 0.96 | ENPEP (0.56) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL2228574 | 0.95 | MME (0.58) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL10715137 | 0.95 | MME (0.58) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL31031588 | 0.93 | SLC7A5 (0.56) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL30390719 | 0.93 | MME (0.55) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL30974501 | 0.93 | ENPEP (0.53) | MMENPY1RNPY2RNPY4RACE | |
| SCHEMBL30839504 | 0.92 | SLC7A5 (0.55) | ENPEPSLC7A5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-14 | — | — | US | claimed |
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | VIP, IAPP, ANXA5 | MME 771/4885NPY1R 259/4885NPY2R 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.